Cargando…
Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach
Autores principales: | Zhu, Mengxuan, Chen, Erbao, Yu, Shan, Xu, Chen, Yu, Yiyi, Cao, Xin, Li, Wei, Zhang, Pengfei, Wang, Yan, Lian, Baofeng, Zhang, Shuirong, Qu, Yueting, Huang, Lujia, Shi, Weiwei, Cui, Yuehong, Qian, Li, Liu, Tianshu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558685/ https://www.ncbi.nlm.nih.gov/pubmed/35851588 http://dx.doi.org/10.1002/cac2.12336 |
Ejemplares similares
-
Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma
por: Li, Wei, et al.
Publicado: (2020) -
Hepatoid adenocarcinoma of the stomach: CT findings
por: Yang, Qian, et al.
Publicado: (2023) -
Clinicopathological and Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach
por: Yang, Jinlin, et al.
Publicado: (2014) -
Hepatoid adenocarcinoma of the stomach: Thirteen case reports and review of literature
por: Zhang, Zheng-Rong, et al.
Publicado: (2020) -
Hepatoid Adenocarcinoma of Stomach: Emphasis on the Clinical Relationship with Alpha-Fetoprotein-Positive Gastric Cancer
por: Chen, Er-Bao, et al.
Publicado: (2019)